Jane Henderson
CIK 1422304 · Chief Financial Officer · last filed 2026-07-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$21.25M
Companies
10
Total Filings
63
Lifetime Open-Market Net
-$5.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APGE | Chief Financial Officer | 158,371 | $134.17 | $21.25M | -$2.38M | 16 | 2026-07-24 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | -$2.31M | 9 | 2025-12-09 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 3 | 2025-08-19 |
| IVERIC bio, Inc. (ISEE) Delisted | Director | 22,088 | $39.95 | $882.4K | $0 | 6 | 2023-05-19 |
| Invivyd, Inc. (ADGI) Delisted | Chief Financial Officer | — | $4.64 | — | $0 | 1 | 2022-02-01 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 4 | 2021-05-10 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | — | — | — | $0 | 2 | 2018-07-11 |
| VYGR | Sr. V.P. & CFO, Corp. Dev. | 0 | $3.04 | $0 | -$1.03M | 4 | 2018-03-26 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-05-23 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Chief Financial Officer & CBO | 125,000 | — | — | $23.5K | 3 | 2008-05-05 |
Recent Filings · Page 2 of 7
63 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-02 | APGE | Notice (144) | −12,000 | -$905.8K | EDGAR |
| 2025-12-23 | APGE | Sell (S) | −1,500 | -$120.0K | EDGAR |
| 2025-12-19 | APGE | Notice (144) | −1,500 | -$116.0K | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −9,398 | $0 | EDGAR |
| 2025-12-05 | APGE | Sell (S) | −1,500 | -$112.5K | EDGAR |
| 2025-12-04 | APGE | Notice (144) | −1,500 | -$111.8K | EDGAR |
| 2025-11-28 | APGE | Sell (S) | −1,500 | -$105.0K | EDGAR |
| 2025-11-25 | APGE | Notice (144) | −1,500 | -$101.8K | EDGAR |
| 2025-11-14 | APGE | Notice (144) | −2,000 | -$125.9K | EDGAR |
| 2025-11-14 | APGE | Sell (S) | −2,000 | -$130.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.